Omega Flex, Inc. — FY2019 Form 10-K Summary
Business Context and Reporting Period
Omega Flex manufactures and sells flexible metal hose, corrugated tubing, proprietary fittings and accessories through distributors, wholesalers, sales representatives and OEMs. Its single operating segment serves residential and commercial construction, general industrial, medical-gas and fuel-containment applications. Products are manufactured in Pennsylvania, Texas and the United Kingdom. The filing covers the fiscal year ended December 31, 2019, with quarterly information for the fourth quarter and full year.
Key products include TracPipe CounterStrike flexible gas piping, AutoFlare and AutoSnap fittings, DoubleTrac and DEF-Trac fuel piping, and MediTrac corrugated medical tubing, which was commercialized in 2019.
Financial Performance and Metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Net sales | $111.360 million | $108.313 million | +2.8% |
| Gross profit | $70.487 million | $66.096 million | +6.6% |
| Gross margin | 63.3% | 61.0% | +230 bps |
| Operating profit | $21.922 million | $26.366 million | -16.9% |
| Operating margin | 19.7% | 24.3% | -460 bps |
| Net income attributable to Omega Flex | $17.286 million | $20.139 million | -14.2% |
| Basic and diluted EPS | $1.71 | $2.00 | -14.5% |
| Cash flow from operations | $16.041 million | $21.058 million | -23.8% |
Fourth-quarter 2019 sales were $29.733 million, gross profit was $19.101 million and net income attributable to Omega Flex was $5.553 million, compared with fourth-quarter 2018 sales of $28.870 million, gross profit of $18.302 million and attributable net income of $6.024 million.
Selling expense increased 11.2% to $19.032 million, including higher consulting costs related to MediTrac, expanded sales staffing, commissions and travel. General and administrative expense increased 39.4% to $24.818 million, principally because of $4.659 million of higher legal and product-liability defense costs, including costs associated with a pending class action, and $1.390 million of higher incentive compensation tied largely to the stock-price increase. Engineering expense declined 2.0% to $4.715 million.
Financial Position, Liquidity and Capital Allocation
- Cash and cash equivalents were $16.098 million at December 31, 2019, down from $32.392 million. The decrease primarily reflected $46.028 million of dividends paid, including a $35.330 million special dividend, and increased inventory purchases.
- Working capital was $25.836 million versus $55.217 million in 2018. Total assets were $60.984 million versus $86.836 million, and total shareholders’ equity was $37.576 million versus $66.321 million.
- Inventory increased 38.9% to $11.078 million, driven by preparation for anticipated MediTrac demand and increased DoubleTrac inventory.
- Operating cash flow was $16.041 million. Investing activities provided $13.719 million, primarily because short-term investments were liquidated; capital expenditures were $1.225 million.
- The company had no borrowings under its unsecured $15.0 million Santander revolving credit facility at year-end and remained in compliance with its covenants. The facility matures December 1, 2022.
- Management stated that existing cash and cash equivalents should meet anticipated cash needs for at least the next 12 months.
- Regular quarterly dividends are expected to continue, but future regular or special dividends remain subject to Board approval and the company’s cash needs, results, capital plans and other factors.
Material Changes Versus the Prior Comparable Period
- Revenue grew modestly, primarily from pricing actions intended to offset higher material costs. Management reported reasonably stable margins despite increases in core component costs.
- Gross margin expanded to 63.3%, but operating and net margins declined because selling, legal, product-liability, administrative and incentive-compensation costs rose substantially.
- Cash and equity declined sharply after the special dividend and regular dividend payments. Short-term investments of $14.944 million held at year-end 2018 were fully liquidated during 2019.
- Inventory increased materially in support of MediTrac commercialization and DoubleTrac availability.
- The company adopted the new lease standard effective January 1, 2019, recording approximately $800,000 of operating lease assets and liabilities initially. The adoption did not materially affect income or cash flow.
- MediTrac was commercialized in 2019 after beta-site activity in 2018; the filing does not provide a separate revenue or profitability figure for the product.
Guidance, Outlook, Risks and Unusual Items
The filing does not provide quantitative revenue, earnings or margin guidance. Management expects liquidity to be sufficient for at least the next 12 months and intends to pursue continued product development and market expansion, including opportunities for MediTrac and other flexible-piping applications.
- The business remains heavily dependent on TracPipe and CounterStrike flexible gas-piping products and on distributor and independent sales networks. Ferguson Enterprises represented approximately 14% to 15% of sales and 22% to 24% of accounts receivable in the relevant periods.
- Construction demand is seasonal and cyclical, with activity generally weaker in winter. Interest rates, housing activity and broader economic conditions may affect demand.
- Stainless steel, nickel, copper, polyethylene and purchased fittings are key inputs. The company relies primarily on one or two suppliers for certain materials and components, creating price and supply-disruption risk.
- Pending product-liability and lightning-related claims, including a Missouri putative class action, could increase legal costs, insurance retentions and liquidity requirements. The company estimated aggregate exposure for current open claims, excluding the class action, at approximately $3.3 million, while acknowledging that ultimate liability cannot be estimated.
- Recorded liabilities for claims and related legal matters were $215,000 at December 31, 2019, compared with $150,000 in 2018. A potential legal liability identified in February 2020 was estimated at $200,000 to $500,000.
- Potential shifts away from fossil fuels and natural gas could reduce demand for the company’s principal flexible gas-piping products.
- Brexit could increase customs, logistics and manufacturing costs for the United Kingdom operation, although management did not expect the effects to be material. The filing also identifies the then-emerging coronavirus outbreak as a potential operational and demand risk, with effects described as uncertain.
- Contractual obligations included $27.595 million of purchase commitments, primarily for core materials, and $787,000 of operating lease obligations. Phantom-stock liabilities totaled $3.201 million, including $1.508 million expected to be paid within one year.
Investor Verification Checklist
- Verify the sustainability of revenue growth and the extent to which future pricing can offset material-cost inflation.
- Assess whether MediTrac generates meaningful volume and returns after the 2019 inventory build and commercialization spending.
- Review the pending Missouri class action, other product-liability claims, insurance coverage and potential cash exposure.
- Evaluate liquidity after the unusually large special dividend and confirm the company’s continuing dividend policy against operating cash flow.
- Monitor distributor concentration, particularly Ferguson Enterprises, and the stability of independent sales organizations.
- Review exposure to natural-gas demand, construction cycles, commodity prices, Brexit-related logistics and broader supply-chain disruptions.
- Confirm the company’s stated effective disclosure controls and internal control over financial reporting, supported by an unqualified auditor opinion.